Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.79
+1.23 (0.59%)
AAPL  273.20
+1.06 (0.39%)
AMD  213.17
-0.67 (-0.31%)
BAC  51.50
+1.09 (2.16%)
GOOG  311.12
+0.20 (0.06%)
META  651.11
+11.81 (1.85%)
MSFT  397.69
+8.69 (2.23%)
NVDA  197.09
+4.24 (2.20%)
ORCL  150.59
+4.45 (3.05%)
TSLA  413.24
+3.86 (0.94%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.